Pfizer Inc

• Revolution Medicines initiated patient treatment in new global Phase 3 clinical trials. • Analysts published bullish notes and raised price targets for the company. • The company reported zero annual revenue and a net loss of $1.13B.

• Moderna and Merck prepare FDA submission for their individualized mRNA melanoma vaccine. • The company reported an annual revenue of $1.94B and net profit of $-2.82B. • Analysts rate the stock as Hold with an average price target of $123.99.

• Positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo boosted shares. • Analysts reaffirmed positive ratings despite price target adjustments for secondary indications. • Argenx reports annual revenue of $4.15B and net profit of $1.29B.

• Bristol Myers Squibb stock gained momentum ahead of major medical conference presentations. • Analysts upgraded targets following strong clinical pipeline updates and commercial growth assets. • The company reported $48.19B annual revenue and $7.05B net profit.

• Eli Lilly's metabolic drugs and pipeline advancements drove strong investor sentiment. • The company reported $65.18B in annual revenue and $20.64B net profit. • Technical indicators show a buy signal with an RSI of 71.633.

• Merck shares rose due to positive oncology pipeline and Phase 3 trial data. • Strategic portfolio expansion and cardiovascular treatments alleviate patent expiration and revenue concerns. • Analysts maintain buy ratings with an average price target of $154.68.